Considering the special relation of human multiple myeloma (MM) to bones, it is of importance to clarify the early steps of bone involvement in this disease. In this work, using bone histomorphometry (including histoenzymologic and kinetic studies for the first time), we have evaluated the bone remodeling (i.e., bone resorption and bone formation rates) of 16 individuals with early MM in comparison with that of 10 with benign monoclonal gammopathy (BMG) and that of 17 patients with previously untreated overt MM. A significantly increased osteoblastic recruitment was observed in the individuals with early MM when compared with those with BMG (P < 0.01). A significant (P < 0.01) increased bone resorption (i.e., eroded surfaces, osteoclast numbers and surfaces) was observed from the early stage of MM in comparison with the BMG status where bone resorption remained within the normal range. At the tissue level, there was no difference in terms of bone resorption between early and overt MM. On the other hand, osteoblast activity was significantly reduced in patients with overt MM (P < 0.05 by comparison with those with early MM).
Introduction
Bone involvement, bone destruction mainly, is a common feature of patients with overt multiple myeloma (MM),' in con-1. Abbreviations used in this paper: BFR, bone formation rates; BMG, benign monoclonal gammopathy; BS, bone surface referent; BV, bone volume referent; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; TNF, tumor necrosis factor; TRAP, tartrate-resistant acid phosphatase; TV, tissue volume referent.
trast to what is observed in other B cell malignancies (1, 2) . Bone involvement is related to an excessive bone resorption encountered in the close vicinity of myeloma cells (3) (4) (5) (6) . This increased resorption is due to the local stimulation of osteoclasts by soluble factors released by myeloma cells and environmental cells, such as IL-1 and tumor necrosis factor (TNF) (3, (7) (8) (9) (10) (11) (12) (13) . The severity of lytic bone lesions is actually correlated with the presence of a marked uncoupling process in patients with advanced MM: increased bone resorption with decreased bone formation (14) . Patients lacking lytic bone lesions and rare osteosclerotic variants have an opposite osteoblastic presentation ( 15) .
Considering the special relation ofmyeloma cells to bone, it is of critical importance to clarify the early steps of bone involvement in this disease. In this work, we OVERT MULTIPLE MYELOMA 17 patients with previously untreated overt MM were included in this study. The diagnostic criteria and the management of these patients have been previously described (20, 21) . There were ten IgG MM, five IgA, and only two Bence Jones. The sex ratio M/F was 1.05.
Bone histomorphometry
Quantitative histology of bone changes was performed as previously described on undecalcified transiliac bone biopsy specimens (5, 14, 15) . BONE 
BIOPSIES
Bone biopsies were performed by one operator of the investigative team under local anesthesia from a standardized point 2 cm below the iliac crest and 2 cm behind the anterosuperior iliac spine. The transiliac bone cores were 8 mm in diameter, according to Frost's recommendations (22) . The specimens were immediately fixed in acidified 70% alcohol and were kept for 24 h at 4VC. They were then dehydrated over a period of 36 h in pure acetone at 4VC.
BONE BIOPSY EMBEDDING AND STAINING PROCEDURES
Biopsy specimens were embedded in a mixture of purified glycol and methyl methacrylates according to the laboratory methods described elsewhere (23) . Infiltration ofbone cores as well as the embedding process were done in a cold environment to preserve bone enzyme activities. 7 /m in thickness sections were cut using a Jung type K microtome equipped with HK3 tungsten carbide knives. Stainings for routine histomorphometry were done by a modification ofGoldner's procedures on eight nonserial sections (24) . Six additional nonserial sections for histochemical identification of tartrate resistant acid phosphatase (TRAP, a histochemical procedure for osteoclasts) activity by a simultaneous coupling method using a-naphtyl phosphate, fast violet B, and L-(+)-sodium tartrate were done (25, 26) .
HISTOMORPHOMETRIC ANALYSIS
Nomenclature, symbols, and units used in this study are those published recently in the report of the American Society for Bone and Mineral Research, Histomorphometry Nomenclature Committee; (27) . Details on the main parameters used in this study have been outlined in the table.
Bone mass parameters. Bone volume (corresponding to the part of cancellous space occupied by trabecular bone), was measured on a Leitziast image analyzer (28) .
Parameters of bone resorption. Measurements of osteoclastic parameters were made on a semiautomatic image analyzer system composed ofa digitizing tablet (Summasketch; Summagraphics) connected to a microcomputer (Macintosh Plus). Microscopic observation was performed with a Leitz Diaplan microscope equipped with a drawing system (Camera Lucida). The analytic programs were developed in our laboratory (29, 30) . Measurements were made with a magnification of 100 using a standard rectangular microphotographic eyepiece of known surface projected over the cancellous space. On Goldner's sections, we have measured eroded surfaces (%). On TRAP-stained sections, only the positive cells in close contact with the calcified trabecular bone were taken into account as osteoclasts. The following parameters were measured: osteoclast number per square millimeter ofsection area and osteoclast surface (%) (ex-active resorption surfaces). The reproducibility of the methods measuring the TRAP-positive cell count was previously evaluated (20, 26 
Results
Bone resorption. A significant increased bone resorption was observed from the stage of early MM in comparison with that of BMG (P < 0.01). This was illustrated by a significant increase in the percentages of eroded surfaces (P < 0.01, Fig. 1 ), of the osteoclast numbers (P < 0.01, Fig. 2 ) and of the osteoclast surfaces (P < 0.01, data not shown). When compared with healthy individuals (26) , 92% of those with early MM presented an excessive bone resorption (i.e., eroded surfaces > 6%, 3 SD above the mean value of age-and sex-matched healthy individuals) whereas individuals with BMG generally retained normal bone resorption. At the tissue level, the parameters of bone resorption did not differ between early and overt MM ( Figs. 1 and 2) . Although there was a trend towards higher percentages of eroded surfaces in patients with higher numbers of osteoclasts, no direct correlation was found between these two parameters.
Bone formation. A strong stimulation of osteoblastic recruitment was observed in the individuals with early MM. As shown in Fig. 3 , BFR in early MM were significantly greater than those of individuals with BMG (P < 0.01). The BFR included BFR/BS (Fig. 3) Bone resorption andformation. When parameters of bone resorption (osteoclast surfaces, %) and those ofBFR were plotted together either in early MM or overt MM, a significant correlation was observed (r = 0.88, P = 0.04 in overt MM; and r = 0.99, P = 0.001 in early MM).
Discussion
Bone involvement is a characteristic feature of MM. Until now, the studies have focused on the presence of an excessive bone resorption associated with a low bone formation in patients with advanced MM (4, 5, 14) . Of importance, we have recently demonstrated that this uncoupling process was di- rectly responsible for the lytic bone lesions in myeloma patients (14 (33, 34) . Osteoblasts produce large amounts of IL-6 (35, 36) , a potent myeloma cell growth factor (17, 18) , and bone resorbing factor (35) , in response to IL-l/ TNF stimuli. Furthermore, a close cooperation between osteoblasts and osteoclasts is necessary to initiate bone resorption (35, 36) . Taken together, these data show clearly that the early osteoblastic recruitment we have presently demonstrated is a critical event in the pathogenesis ofhuman MM. This stimulation could initiate (a) early myeloma cell growth via the production of IL-6, a potent myeloma cell growth factor (17, 18) , by osteoblasts (35, 36) . Other cytokines such as granulocyte macrophage-colony stimulating factor (GM-CSF) and IL-3, two other myeloma cell growth cofactors (37) produced by osteoblasts (38) , could be involved (b) early excessive bone resorption, via the same factors (IL-6, IL-3, and GM-CSF) involved in the generation of new osteoclasts and bone resorption in synergy with IL-l and TNF (35, (39) (40) (41) (42) (43) .
A last point deserves some comments. Although it is not recommended to manage subclinical MM with chemotherapy until overt malignancy (i.e., anemia, bone lesions on radiography) was observed, our data could change this point of view. Furthermore, some bone sparing agents such as diphosphonates could be useful in early MM since they appeared to be beneficial as long-term treatment of mouse plasmacytoma (44) and overt human MM (45, 46) . 
